Answers are grounded in this paper and cite their sources.
Review highlights strategies to enhance tumor targeting and penetration of nanoparticles in cancer therapy, suggesting significant implications for treatment outcomes.
Recent advances in the development of tumor-targeting nanoparticles (NPs) significantly enhance cancer therapies by effectively increasing the therapeutic window of drugs, improving the response of tumor cells, and augmenting anti-tumor immunity. However, the understanding of the tumor-targeting process remains elusive because of the complex in vivo behavior of nanoparticles. Various factors are reported to alter this process; however, systematic studies on tumor-targeting mechanisms remain limited. In this review, an overview of current strategies for improving tumor targeting and their applications in cancer chemotherapy and immunotherapy, with a focus on the advancement of the understanding of various in vivo barriers for effective tumor targeting and penetration is provided.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: